Sven Asmussen1, Hiroshi Ito1, Daniel L Traber1, Jae W Lee2, Robert A Cox1, Hal K Hawkins1, Daniel F McAuley3, David H McKenna4, Lillian D Traber1, Hanjing Zhuo2, Jennifer Wilson2, David N Herndon5, Donald S Prough1, Kathleen D Liu2, Michael A Matthay2, Perenlei Enkhbaatar1. 1. Department of Anesthesiology, The University of Texas Medical Branch, Galveston, Texas, USA. 2. Departments of Medicine & Anesthesiology, Cardiovascular Research Institute, The University of California San Francisco, San Francisco, California, USA. 3. Departments of Medicine & Anesthesiology, Cardiovascular Research Institute, The University of California San Francisco, San Francisco, California, USA Centre for Infection and Immunity, The Queen's University of Belfast, Belfast, Northern Ireland, UK. 4. Production Assistance in Cellular Therapy, University of Minnesota, Saint Paul, Minnesota, USA. 5. Shriners Hospital for Children, Galveston, Texas, USA.
Abstract
BACKGROUND: Human bone marrow-derived mesenchymal stem (stromal) cells (hMSCs) improve survival in mouse models of acute respiratory distress syndrome (ARDS) and reduce pulmonary oedema in a perfused human lung preparation injured with Escherichia coli bacteria. We hypothesised that clinical grade hMSCs would reduce the severity of acute lung injury (ALI) and would be safe in a sheep model of ARDS. METHODS: Adult sheep (30-40 kg) were surgically prepared. After 5 days of recovery, ALI was induced with cotton smoke insufflation, followed by instillation of live Pseudomonas aeruginosa (2.5×10(11) CFU) into both lungs under isoflurane anaesthesia. Following the injury, sheep were ventilated, resuscitated with lactated Ringer's solution and studied for 24 h. The sheep were randomly allocated to receive one of the following treatments intravenously over 1 h in one of the following groups: (1) control, PlasmaLyte A, n=8; (2) lower dose hMSCs, 5×10(6) hMSCs/kg, n=7; and (3) higher-dose hMSCs, 10×10(6) hMSCs/kg, n=4. RESULTS: By 24 h, the PaO2/FiO2 ratio was significantly improved in both hMSC treatment groups compared with the control group (control group: PaO2/FiO2 of 97±15 mm Hg; lower dose: 288±55 mm Hg (p=0.003); higher dose: 327±2 mm Hg (p=0.003)). The median lung water content was lower in the higher-dose hMSC-treated group compared with the control group (higher dose: 5.0 g wet/g dry [IQR 4.9-5.8] vs control: 6.7 g wet/g dry [IQR 6.4-7.5] (p=0.01)). The hMSCs had no adverse effects. CONCLUSIONS: Human MSCs were well tolerated and improved oxygenation and decreased pulmonary oedema in a sheep model of severe ARDS. TRAIL REGISTRATION NUMBER: NCT01775774 for Phase 1. NCT02097641 for Phase 2. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
BACKGROUND: Human bone marrow-derived mesenchymal stem (stromal) cells (hMSCs) improve survival in mouse models of acute respiratory distress syndrome (ARDS) and reduce pulmonary oedema in a perfused human lung preparation injured with Escherichia coli bacteria. We hypothesised that clinical grade hMSCs would reduce the severity of acute lung injury (ALI) and would be safe in a sheep model of ARDS. METHODS: Adult sheep (30-40 kg) were surgically prepared. After 5 days of recovery, ALI was induced with cotton smoke insufflation, followed by instillation of live Pseudomonas aeruginosa (2.5×10(11) CFU) into both lungs under isoflurane anaesthesia. Following the injury, sheep were ventilated, resuscitated with lactated Ringer's solution and studied for 24 h. The sheep were randomly allocated to receive one of the following treatments intravenously over 1 h in one of the following groups: (1) control, PlasmaLyte A, n=8; (2) lower dose hMSCs, 5×10(6) hMSCs/kg, n=7; and (3) higher-dose hMSCs, 10×10(6) hMSCs/kg, n=4. RESULTS: By 24 h, the PaO2/FiO2 ratio was significantly improved in both hMSC treatment groups compared with the control group (control group: PaO2/FiO2 of 97±15 mm Hg; lower dose: 288±55 mm Hg (p=0.003); higher dose: 327±2 mm Hg (p=0.003)). The median lung water content was lower in the higher-dose hMSC-treated group compared with the control group (higher dose: 5.0 g wet/g dry [IQR 4.9-5.8] vs control: 6.7 g wet/g dry [IQR 6.4-7.5] (p=0.01)). The hMSCs had no adverse effects. CONCLUSIONS: Human MSCs were well tolerated and improved oxygenation and decreased pulmonary oedema in a sheep model of severe ARDS. TRAIL REGISTRATION NUMBER: NCT01775774 for Phase 1. NCT02097641 for Phase 2. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Matthias Lange; Atsumori Hamahata; Daniel L Traber; Rhykka Connelly; Yoshimitsu Nakano; Lillian D Traber; Frank C Schmalstieg; David N Herndon; Perenlei Enkhbaatar Journal: Burns Date: 2012-05-29 Impact factor: 2.744
Authors: M B Amato; C S Barbas; D M Medeiros; R B Magaldi; G P Schettino; G Lorenzi-Filho; R A Kairalla; D Deheinzelin; C Munoz; R Oliveira; T Y Takagaki; C R Carvalho Journal: N Engl J Med Date: 1998-02-05 Impact factor: 91.245
Authors: M D Eisner; T Thompson; L D Hudson; J M Luce; D Hayden; D Schoenfeld; M A Matthay Journal: Am J Respir Crit Care Med Date: 2001-07-15 Impact factor: 21.405
Authors: Sebastian Rehberg; Yusuke Yamamoto; Linda E Sousse; Collette Jonkam; Yong Zhu; Lillian D Traber; Robert A Cox; Donald S Prough; Daniel L Traber; Perenlei Enkhbaatar Journal: Crit Care Med Date: 2013-12 Impact factor: 7.598
Authors: Kazunori Murakami; Lars J Bjertnaes; Frank C Schmalstieg; Roy McGuire; Robert A Cox; Hal K Hawkins; David N Herndon; Lillian D Traber; Daniel L Traber Journal: Crit Care Med Date: 2002-09 Impact factor: 7.598
Authors: V Marco Ranieri; Gordon D Rubenfeld; B Taylor Thompson; Niall D Ferguson; Ellen Caldwell; Eddy Fan; Luigi Camporota; Arthur S Slutsky Journal: JAMA Date: 2012-06-20 Impact factor: 56.272
Authors: Darcy E Wagner; Wellington V Cardoso; Sarah E Gilpin; Susan Majka; Harald Ott; Scott H Randell; Bernard Thébaud; Thomas Waddell; Daniel J Weiss Journal: Ann Am Thorac Soc Date: 2016-08
Authors: Daniel R Potter; Byron Y Miyazawa; Stuart L Gibb; Xutao Deng; Padma P Togaratti; Roxanne H Croze; Amit K Srivastava; Alpa Trivedi; Michael Matthay; John B Holcomb; Martin A Schreiber; Shibani Pati Journal: J Trauma Acute Care Surg Date: 2018-02 Impact factor: 3.313
Authors: Michael A Matthay; Carolyn S Calfee; Hanjing Zhuo; B Taylor Thompson; Jennifer G Wilson; Joseph E Levitt; Angela J Rogers; Jeffrey E Gotts; Jeanine P Wiener-Kronish; Ednan K Bajwa; Michael P Donahoe; Bryan J McVerry; Luis A Ortiz; Matthew Exline; John W Christman; Jason Abbott; Kevin L Delucchi; Lizette Caballero; Melanie McMillan; David H McKenna; Kathleen D Liu Journal: Lancet Respir Med Date: 2018-11-16 Impact factor: 30.700